jRCT2033200096RecruitingNot Applicable
The clinical study to evaluate the safety of the regenerative medicine and the gene therapy by the autologous transplantation of human LCAT gene transduced human pre-adipocyte (LCAT-Trial-24 weeks)
Not provided0 sites3 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 3
- Primary Endpoint
- Appearance of RCR after administration of clinical trial products
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Single Arm Study
- Intervention Model
- Single Assignment
- Primary Purpose
- Treatment Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 16age old over to No limit (—)
- Sex
- All
Inclusion Criteria
- •Patients who meet all of the following conditions.
- •Patients with a definitive diagnosis of familial LCAT deficiency based on the following diagnostic criteria
- •(1) LCAT gene mutation has been confirmed in genetic diagnosis (having amino acid residue substitution in LCAT protein)
- •(2) Low HDL-cholesterol (less than 25 mg/dL) is observed, and one or some of following complications typical for this disease is detected; corneal opacification, renal dysfunction (proteinuria), hemolytic anemia
- •(3) Blood LCAT activity (artificial substrate method) is below the detection limit (reference standard value 382-512U)
- •Patients older than
- •Patient who provides written informed consent. If the patient is a minor, written consent must be obtained from the patient as well as a parent or guardian.
Exclusion Criteria
- •Patients who meet any of the following conditions are not included.
- •Patients who are not expected to express full-length LCAT protein due to frameshift or the appearance of stop codon by insertion/deletion mutation in LCAT gene
- •Patients whose mutant LCAT protein cannot be detected in blood by immunological method (ELISA or immunoprecipitation western blot)
- •Patients with advanced liver disease (fulminant hepatitis, cirrhosis, etc.) that affects lipid metabolism
- •Patients with advanced renal disease (transferred or planned to transfer to dialysis)
- •Patients who received LCAT protein replacement therapy by whole blood or plasma transfusion within 1 month before obtaining written consent.
- •Patients who are considered to be difficult to perform subcutaneous liposuction
- •Pregnant and lactating women. In the case of female patients who can become pregnant (all women except those who have undergone permanent contraception or those who have been postmenopausal*), those who do not agree to contraception during the clinical trial period (up to 24 weeks after administration). In addition, in the case of male patients, patients who do not agree to contraception during the clinical trial period (up to 24 weeks after administration).
- •Patients with other similar diseases that are not caused by LCAT deficiency and have low HDL-cholesterol (Apo A-1 abnormality/Tangier disease)
- •Patients with a history of hypersensitivity to the components of this clinical trial product or the components (fetal bovine serum and human albumin) used in the manufacturing process of this clinical trial product.
- •Other patients who are deemed unsuitable by the investigator or the sub-investigator
Outcomes
Primary Outcomes
Appearance of RCR after administration of clinical trial products
Appearance of RCR after administration of clinical trial products
Tumorigenesis of the administration site after administration of the clinical trial product
Tumorigenesis of the administration site after administration of the clinical trial product (complementarily evaluated by the following 2 items) (A) MRI examination (B) Tumorigenicity test of the clinical trial product in immunodeficient (NSG) mice
Appearance of anti-LCAT antibody after administration of clinical trial products
Appearance of anti-LCAT antibody after administration of clinical trial products
Occurrence of unexpected serious adverse events other than (1) to (3)
Occurrence of unexpected serious adverse events other than (1) to (3)
Secondary Outcomes
- Type, frequency and severity of adverse events
- LCAT activity(during the observation period)
- Blood LCAT concentration(during the observation period)
Investigators
Similar Trials
Recruiting
Phase 1
The clinical study to evaluate the safety of the regenerative medicine and the gene therapy by the autologous transplantation of human LCAT gene transduced human pre-adipocyteFamilial LCAT deficiencyCorneal opacity, Renal dysfunction, Hemolytic anemiaD007863JPRN-jRCT2033200096Yokote Koutaro3
Active, not recruiting
Not Applicable
Clinical Trial for the Evaluation of the Safety of the Product in Study Cream Gel through the Evaluation of Skin Compatibility under Normal Conditions of UseHypersensitivityN06.850.210RBR-8fnb6xxKosmosciense Ciência e Tecnologia Cosm Imp Exp Ltda
Completed
Phase 2
A clinical of Appetol syrup in children suffering from non-specific anorexia (loss of appetite)CTRI/2014/07/004756ARJUN HEALTHCARE50
Recruiting
Phase 3
Clinical trial of Lipidil Tablet in comparison with Atorvastatin in patients with abnormal amount of lipids.CTRI/2014/09/005015Arjun Healthcare80
Completed
Phase 2
A clinical trial to study the effect of AHPL/AYTAB/0313 in patients suffering from arthritis of knee(s)CTRI/2015/09/006177Ari Healthcare Pvt Ltd48